<?xml version="1.0" encoding="UTF-8"?>
<p>Chloroquine phosphate displayed apparent efficacy and acceptable safety against SARS-COV-2 in multicenter clinical trials conducted in China (
 <xref rid="B74" ref-type="bibr">74</xref>). The use of this drug appears in the Guidelines for the Prevention, Diagnosis, and Treatment of Pneumonia Caused by SARS-CoV-2 issued by the National Health Commission of the People's Republic of China. Another recent study suggested chloroquine phosphate tablet (500 mg twice per day for 10 days) against SARS-COV-2 (
 <xref rid="B74" ref-type="bibr">74</xref>). Although chloroquine has long been used to treat malaria and amebiasis, 
 <italic>Plasmodium falciparum</italic> has developed widespread resistance to it (
 <xref rid="B75" ref-type="bibr">75</xref>). Furthermore, an overdose of chloroquine was known to cause acute poisoning and death (
 <xref rid="B76" ref-type="bibr">76</xref>) which limits its utilization in clinical practices.
</p>
